Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens
Autore:
Simon, JA; Symons, JP;
Indirizzi:
Parke Davis Pharmaceut Res, Ann Arbor, MI 48105 USA Parke Davis PharmaceutRes Ann Arbor MI USA 48105 Ann Arbor, MI 48105 USA Womens Hlth Res Ctr, Laurel, MD USA Womens Hlth Res Ctr Laurel MD USAWomens Hlth Res Ctr, Laurel, MD USA
Titolo Testata:
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
fascicolo: 5, volume: 8, anno: 2001,
pagine: 321 - 327
SICI:
1072-3714(200109/10)8:5<321:UBDIOC>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
ENDOTHELIAL GROWTH-FACTOR; POSTMENOPAUSAL WOMEN; OSTEOPOROSIS; ENDOMETRIUM; DENSITY; CELLS; HRT;
Keywords:
hormone replacement therapy bleeding; treatment adherence; norethindrone; ethinyl estradiol;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Symons, JP Parke Davis Pharmaceut Res, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA Parke Davis Pharmaceut Res 2800 Plymouth Rd Ann Arbor MI USA 48105
Citazione:
J.A. Simon e J.P. Symons, "Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens", MENOPAUSE, 8(5), 2001, pp. 321-327

Abstract

Objective: To determine whether there are differences between continuous combined hormone replacement therapies on bleeding control. Design: Nine hundred and forty-five postmenopausal women were randomized to one of seven double-blind treatment groups (placebo, 0.25 mg norethindrone acetate (NA)/5 mug ethinyl estradiol (EE), 1 mg NA/5 mug EE, 0.5 mg NA/10mug EE, 1 mg NA/10 mug EE, 5 mug EE, and 10 mu EE) or unmasked 0.625 mg conjugated equine estrogens (CEE)/2.5 mg medroxyprogesterone acetate (MPA). Treatment was for 12 months; subjects kept daily diaries recording whether they had bleeding and/or spotting. Results: The results focused on currently commercially available hormone replacement therapy products (femhrt [1 mg NA/5 mug EE] and Prempro [0.625 mg CEE/2.5 mg MPA]) as well as a high-dose NA/EE dose combination (1/10) over the first 6 months of use, the most critical period in establishing treatment adherence. At the end of month 6 there was a greater incidence of amenorrhea with both NA/EE dose combinations compared with CEE/MPA (p = 0.009 for 1 mg NA/5 mug EE and p = 0.006 for 1 mg NA/10 pg EE). Statistically significantly more women were amenorrheic at every month based on cumulative amenorrhea for 1 mg NA/5 mug (p < 0.05) compared with CEE/MPA; at months 3 and 6 more women were amenorrheic on 1 mg NA/10 mug EE compared with CEE/MPA using the cumulative amenorrhea parameter. Conclusions: The results indicate that statistically significantly more women attained amenorrhea based on various parameters when administered continuous combined NA/EE compared with CEE/MPA. The potential for long-term treatment compliance based on better bleeding control may optimize the opportunity to prevent osteoporosis as well as other associated health benefits.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/04/20 alle ore 20:09:36